Abstract:Since 1992, the study of biological functions of HIV-1 gp41 has made great progress. Experimental evidence from several research groups demonstrated that gp41 has a putative cellular receptor. A recombinant soluble gp41 (aa539–684) and gp41 immunosuppressive peptide (aa583–599) could bind to human B lymphocytes and monocytes, but weakly bind to T lymphocytes. It was found that gp41 contains two cellular binding sites (aa583–599 and 641–675). GP41 could selectively inhibit cell proliferation of human T, B lymphocytes and monocytes, enhance human MHC class I, II and ICAM-1 molecule expression on cell surface. Gp41 binding proteins and a monoclonal antibody against the first binding site could inhibit this modulation effect. Amino acid sequence homology exists between gp41 and human type I interferons, and the homologous region is located in the first binding site on gp41 and in the receptor binding site on type I interferons. Studies in other groups indicate that both binding sites in gp41 may be associated with HIV infection of cells. Peptides containing two binding sites could respectively inhibit HIV infection of cells. A monoclonal antibody recognizing the second binding site could neutralize lab-strains and recently separated strains of HIV-1. Besides, antibodies against two regions (homologous with gp41 binding sites) of SIV transmembrane protein gp32 could protect macaques from SIV infection. These results suggest that the study of gp41 binding sites and cellular receptor could contribute to understanding the mechanism of HIV infection and to developing HIV vaccine and anti-HIV drugs.

Affinity Capillary Electrophoresis: Study of the Binding of HIV-1 Gp 41 with a Membrane Protein (P45) on the Human B Cell Line, Raji

HIV-1 Gp41 Binds to Several Proteins on the Human B-cell Line, Raji.

Characterization of Interaction Between C-domain on HIV-1 Gp41 and the Putative Receptor Protein P62.

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

HIV-1 Gp41 by N-domain Binds the Potential Receptor Protein P45.

The Human Monocyte Cell Line U937 Binds HIV-1 Gp41 by Proteins of 37, 45, 49, 62 and 92 Kda.

HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human raji cell mhc class I and II expression by gp41

The C Domain of HIV-1 Gp41 Binds the Putative Cellular Receptor Protein P62.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

HIV-2 Transmembrane Protein gp36 Binds to the Putative Cellular Receptor Proteins P45 and P62

Enhancement of HIV-1 gp41 binding to raji cells by pwm, lps, interferon-γ and interleukin-6

Biological Function Of Hiv-1 Transmembrane Protein Gp41 - A Study On A Putative Cellular Receptor Of Gp41

Binding of HIV gp41 with its Receptors Immobilized at Liquid/Solid Interface Studied by Surface Plasmon Resonance

Human interferon-β inhibits binding of HIV-1 gp41 to lymphocyte and monocyte cells and binds the potential receptor protein P50 for HIV-1 gp41

HIV-1 Gp41 Binding to Human T- and B-lymphocytes and Monocytes is Modulated by Phorbol Myristate Acetate (PMA)

Identification of Critical Antibody-Binding Sites in the HIV-1 Gp41 Six-Helix Bundle Core As Potential Targets for HIV-1 Fusion Inhibitors

Biological Function of H1V-1 Transmembrane Protein Gp41

Selection of a Novel Gp41-Specific HIV-1 Neutralizing Human Antibody by Competitive Antigen Panning.

A Common Immunological Epitope Existing between HIV-1 gp41 and Human Interferon-α and -β

' s report Anti-HIV-1 activity of cellulose acetate phthalate : Synergy with soluble CD 4 and induction of Title : " dead-end " gp 41 six-helix bundles

Study of the Cyclic Peptide Binding to HIV-1 Gp41 NHR